Goodwin advised RA Capital and Versant Ventures as joint lead investors on a €66 million Series A financing round for German T-knife GmbH. The round took place also with significant participation from the existing investors Andera Partners and Boehringer Ingelheim Venture Fund (BIVF).
T-knife is a next-generation adoptive T-cell company utilizing its proprietary humanized T-cell receptor (HuTCR) mouse platform technology to treat solid tumors. The company was spun out of Max-Delbruck Center for Molecular Medicine with support of Charité University Hospital in Berlin in 2018.
RA Capital Management headquartered in Boston is a multi-stage investment manager with a focus on healthcare and life sciences.
Versant Ventures is a leading healthcare investment firm headquartered in San Francisco with $2.4 billion under management.
The team advising RA Capital and Versant Ventures was led by Gregor Klenk and Mitchell Bloom and included Martin Prokoph, Heiko Penndorf, Stephanie Philbin, Tim Worden, Daniel Karelitz, Joana Pamukova, Talitha Shkopiak, Alexander Plaum, Kimberley Maruncic and Qing Han.